LEXICON PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $10.10 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-05
- LEXICON PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $10.10M, a 67.21% decline from fiscal 2024.
- LEXICON PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $30.80M, a 30.63% decline from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $44.40M, a 127.69% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $19.50M, a 13.37% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $10.10M 10-K · filed 2026-03-05 |
| 2024-12-31 | $30.80M 10-K · filed 2025-03-07 |
| 2023-12-31 | $44.40M 10-K · filed 2024-03-25 |
| 2022-12-31 | $19.50M 10-K · filed 2023-03-03 |
| 2021-12-31 | $17.20M 10-K · filed 2022-03-10 |
| 2020-12-31 | $20.40M 10-K · filed 2021-03-12 |
| 2019-12-31 | $35.30M 10-K · filed 2020-03-12 |
| 2018-12-31 | -$22.90M 10-K · filed 2019-03-15 |
| 2017-12-31 | $121.10M 10-K · filed 2018-03-01 |
| 2016-12-31 | $54.80M 10-K · filed 2017-03-06 |
| 2015-12-31 | $1.20M 10-K · filed 2016-03-11 |
| 2014-12-31 | $35.80M 10-K · filed 2015-03-12 |
| 2013-12-31 | $28.20M 10-K · filed 2014-03-07 |
| 2012-12-31 | $33.50M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |